The Asia Pacific botulinum toxin market was valued at US$ 925.29 million in 2023 and is expected to reach US$ 2,743.18 million by 2031; it is estimated to register a CAGR of 14.6% from 2023 to 2031.
Cosmetic surgery and injectable botulinum toxin are among the most popular noninvasive rejuvenation procedures. According to the ISAPS, in 2020, the botulinum toxin treatment was the leading noninvasive cosmetic procedure performed worldwide. Moreover, the use of botulinum toxin type A-based (BoNTA) cosmetic facial treatments are performed to improve the aesthetics of the upper and lower face. In the last decade, a facial rejuvenation procedure has gained significant popularity over different types of traditional surgeries. According to the ISAPS, ~7.3 million botulinum toxin procedures were performed globally in 2020. Thus, the surge in the adoption of botulinum toxin in facial aesthetic procedures for both men and women from all age groups is driving the botulinum toxin market growth.
The Asia Pacific botulinum toxin market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. The number of people suffering from headache or migraine has been rising every year, and botulinum toxin has been proven effective in reducing the frequency and severity of headaches in patients with chronic migraine. Moreover, the rising awareness of cosmetic procedures such as skin rejuvenation to improve aesthetic appeal and an increase in healthcare expenditure help to boost the growth of the botulinum toxin market in the region. The aesthetic industry in Japan has witnessed massive growth in the past. The industry is well-developed and has access to a wide range of aesthetic products. The industry is highly regulated, and hence, only licensed medical doctors perform aesthetic procedures. The market in the country is mainly driven by the increasing number of consumers willing to invest in altering and maintaining their looks. According to the ISAPS, in 2021, 458,749 botulinum toxin procedures were performed across the country. The country ranks 3rd among all the countries performing nonsurgical aesthetic procedures in the world, with share of 6.3% of the total procedures performed in the world.
Various international companies have obtained approvals for their products that treat muscle spasticity. Thus, Japanese firms have taken strategic initiatives to secure their positions in the market. In June 2021, Teijin Pharma Limited and Merz Therapeutics, a business of the Merz Group, together announced that Teijin Pharma had been granted additional approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin (incobotulinumtoxinA). To treat lower limb spasticity, Xeomin would be used in the form of intramuscular injection in 50, 100, or 200 units. This strategic move has benefited both companies for the successful launch of Xeomin to treat spasticity indication in Japan. Thus, such instances are expected to encourage more players to develop botulinum toxin for different medical conditions to enter the Japanese market.
The Asia Pacific botulinum toxin market is categorized into product, application, end user, and country.
Based on product, the Asia Pacific botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held a larger share of Asia Pacific botulinum toxin market share in 2023.
In terms of application, the Asia Pacific botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held a larger share of Asia Pacific botulinum toxin market in 2023. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow’s feet, square jaw/ masseter, and others.
By end user, the Asia Pacific botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held the largest share of Asia Pacific botulinum toxin market in 2023.
Based on country, the Asia Pacific botulinum toxin market is segmented into Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific. Japan dominated the Asia Pacific botulinum toxin market share in 2023.
Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Medytox Inc, Galderma SA, Hugel Inc, and Lanzhou Institute of Biological Products Co Ltd are some of the leading companies operating in the Asia Pacific botulinum toxin market.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 925.29 Million |
| Market Size by 2031 | US$ 2,743.18 Million |
| CAGR (2023 - 2031) | 14.6% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Botulinum Toxin Market is valued at US$ 925.29 Million in 2023, it is projected to reach US$ 2,743.18 Million by 2031.
As per our report Asia Pacific Botulinum Toxin Market, the market size is valued at US$ 925.29 Million in 2023, projecting it to reach US$ 2,743.18 Million by 2031. This translates to a CAGR of approximately 14.6% during the forecast period.
The Asia Pacific Botulinum Toxin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Botulinum Toxin Market report:
The Asia Pacific Botulinum Toxin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Botulinum Toxin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Botulinum Toxin Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Botulinum Toxin Market
